Navigation Links
Alzheimer's Drug Discovery Foundation Hosts 10th International Conference on Alzheimer's Drug Discovery - September 14-15
Date:9/1/2009

Latest Trends and Research Released on Alzheimer's Disease by Academic and Biotech Industry Scientists

NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- The 10th International Conference on Alzheimer's Drug Discovery, hosted by the Alzheimer's Drug Discovery Foundation and the only scientific conference focusing solely on the discovery and development of innovative drugs targeting Alzheimer's disease and related dementias, will convene September 14-15, 2009 at the Hyatt Regency in Jersey City, N.J.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090805/DC57332LOGO)

More than 30 leading international experts from academia and early-stage biotechnology companies will present and discuss their most current research. The meeting draws an audience of academic and industry scientists engaged in drug discovery research for neurodegenerative diseases. Because of ADDF's venture philanthropy focus, the conference is also open to business development and licensing professionals, alliance management professionals, venture capitalists, and other investors in biotechnology.

"We are proud to feature the accomplishments of our funded investigators and other researchers working on innovative approaches to drug discovery for Alzheimer's disease and related dementias," says Howard Fillit, MD, Executive Director of Alzheimer's Drug Discovery Foundation. "Our sole focus is accelerating the discovery of effective new treatments for Alzheimer's disease- bridging the gap that currently exists between basic research and later-stage drug development.

The conference program will focus on four major areas of study:

Neuroprotection and Prevention

Chair: Dr. Frank Longo, MD, PhD, Stanford University

Anti-Amyloid and Protein Misfolding

Chair: Michael Wolfe, PhD, Brigham and Women's Hospital

Anti-Tangles and Frontotemporal Dementia

Chair: Jeff Kuret, PhD, Ohio State University

Alternative Strategies: New Targets for Alzheimer's Disease Therapy

Chair: Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

The program will feature two plenary sessions: "Bridging Neurocognitive Aging and Disease Modification," by Michaela Gallagher, PhD, Johns Hopkins; and "TDP-43 as a New Target for Neurodegenerative Disease," by Virginia Lee, PhD, MBA, University of Pennsylvania.

The Alzheimer's Drug Discovery Foundation will also present the 2009 ADDF Young Investigators Scholarships, highly prestigious scholarships recognizing the early research achievements of ten younger scientists from academia.

The 10th International Conference on Alzheimer's Drug Discovery is sponsored by Pfizer Inc.; Elan Pharmaceuticals; Martek Biosciences Corporation; Schering-Plough; Allon Therapeutics, Inc.; JSW Lifesciences; Abbott; The American Journal of Geriatric Pharmacotherapy; Apredica; Intra-Cellular Therapies, Inc.; and Rhenovia Pharma.

For Conference Participants: To view the complete program schedule, to apply to register for the conference, and for information on accommodations, visit www.alzdiscovery.org.

About the Alzheimer's Drug Discovery Foundation

ADDF (www.alzdiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. We award grants to leading scientists conducting breakthrough drug discovery research. ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research. Since 1998, we have received over 1,600 requests to fund new ideas for Alzheimer's drugs. For all, we provided expert reviews and recommendations to advance their programs. We granted more than $35 million to fund more than 240 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 12 countries. The ADDF Website carries the latest, vetted news on Alzheimer's disease, updated weekly.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
2. Allegiance Equity Corporation announces collaboration with Canadian Dairy Commission and Guelph Food Technologies Corporation for Alzheimers and Dementia formulation GG-XT
3. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
4. Discovery of natural odors could help develop mosquito repellents
5. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
6. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
7. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
8. New method may accelerate drug discovery for difficult diseases like Parkinsons
9. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
10. Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration
11. Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):